Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs

• Main Authors: Albino Petrone, Michela Quartieri, Cinzia Falcone, Elina Suffredini, Marta Brandani, Gaetano Francesco Mauro
• Format: Article
• Language: English
• Published: PAGEPress Publications 2013-09-01
• Series: Italian Journal of Medicine
• Subjects: aripiprazole, neuroleptic malignant syndrome, neuroleptic drugs.
• Online Access: http://www.italjmed.org/index.php/ijm/article/view/422
• ISSN: 1877-9344; 1877-9352

Aripiprazole is a 2^nd generation antipsychotic medication, atypical neuroleptic used for treatment of schizophrenia improving symptoms such as hallucinations, delusions, and disorganized thinking. A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during aripiprazole treatment in the worldwide clinical database. The disease is characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia. We report on a 63-year old woman with depression syndrome who developed neuroleptic malignant syndrome after twelve days of aripripazole 5 mg per day. Our case is added to the small number already described and suggests the need for caution when aripripazole is added to increase the effect of other antipsychotics.